Robin Kate Kelley

List of Publications by Year
in descending order

56 papers	12,935 citations	126907 33 h-index	155660 55 g-index
59 all docs	59 docs citations	59 times ranked	9999 citing authors

#	Article	IF	Citations
1	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	30.5	2,757
2	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 2018, 379, 54-63.	27.0	1,677
3	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 2022, 76, 681-693.	3.7	1,495
4	Cholangiocarcinoma â€" evolving concepts and therapeutic strategies. Nature Reviews Clinical Oncology, 2018, 15, 95-111.	27.6	1,051
5	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	10.7	620
6	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018, 36, 276-282.	1.6	524
7	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	6.4	416
8	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	1.6	350
9	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
10	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>â€158 and <scp>KEYNOTE</scp>â€028 studies. International Journal of Cancer, 2020, 147, 2190-2198.	5.1	288
11	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	1.6	257
12	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusionâ€"Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	9.4	254
13	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 995-1008.	10.7	237
14	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. Journal of Clinical Oncology, 2022, 40, 379-379.	1.6	235
15	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discovery, 2015, 5, 1040-1048.	9.4	226
16	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. The Lancet Gastroenterology and Hepatology, 2021, 6, 803-815.	8.1	205
17	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
18	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. Journal of Clinical Oncology, 2017, 35, 4073-4073.	1.6	133

#	Article	IF	Citations
19	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	13.2	126
20	Futibatinib, an Irreversible FGFR1â€“4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study. Cancer Discovery, 2022, 12, 402-415.	9.4	119
21	Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer, 2015, 15, 206.	2.6	103
22	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist, 2017, 22, 804-810.	3.7	91
23	Harnessing big â€˜omicsâ€™ data and AI for drug discovery in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 238-251.	17.8	90
24	Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology, 2018, 2, 1-12.	3.0	86
25	Nivolumab in patients with advanced hepatocellular carcinoma and Childâ€Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer, 2019, 125, 3234-3241.	4.1	73
26	Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?. Clinical Colorectal Cancer, 2011, 10, 73-80.	2.3	72
27	Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.. Journal of Clinical Oncology, 2021, 39, 265-265.	1.6	70
28	Hepatocellular Carcinoma â€” Origins and Outcomes. New England Journal of Medicine, 2021, 385, 280-282.	27.0	60
29	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 4795-4804.	7.0	58
30	Genomic Sequencing: Assessing The Health Care System, Policy, And Big-Data Implications. Health Affairs, 2014, 33, 1246-1253.	5.2	53
31	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 3537-3545.	7.0	52
32	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open, 2020, 5, e000714.	4.5	51
33	Secondâ€line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer, 2019, 125, 4426-4434.	4.1	49
34	Atezolizumab plus Bevacizumab â€” A Landmark in Liver Cancer. New England Journal of Medicine, 2020, 382, 1953-1955.	27.0	44
35	Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 2021, 98, 102221.	7.7	43
36	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43

#	Article	IF	Citations
37	Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology, 2021, 39, 266-266.	1.6	41
38	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. Advances in Therapy, 2020, 37, 2678-2695.	2.9	37
39	Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 13-25.	4.9	31
40	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. Cancer Research, 2021, 81, CT010-CT010.	0.9	28
41	Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. Clinical Liver Disease, 2020, 15, 53-58.	2.1	23
42	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 38-47.	7.7	20
43	Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncology, The, 2015, 16, 1279-1281.	10.7	19
44	ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology, 2017, 35, TPS4142-TPS4142.	1.6	17
45	Biliary Tract Cancers: Finding Better Ways to Lump and Split. Journal of Clinical Oncology, 2015, 33, 2588-2590.	1.6	14
46	Cases of Spontaneous Tumor Regression in Hepatobiliary Cancers: Implications for Immunotherapy?. Journal of Gastrointestinal Cancer, 2015, 46, 161-165.	1.3	13
47	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2020, 25, e1825-e1836.	3.7	13
48	Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer, 2021, 10, 561-571.	7.7	11
49	Novel Therapeutics in Hepatocellular Carcinoma: How Can We Make Progress?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e137-e142.	3.8	10
50	Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. British Journal of Cancer, 2022, 126, 569-575.	6.4	10
51	Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time?. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 303-309.	4.9	7
52	A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer Research, 2014, 34, 7357-60.	1.1	7
53	Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transplantation, 2012, 18, 509-513.	2.4	5
54	Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. Journal of Molecular Diagnostics, 2022, 24, 351-364.	2.8	5

#	Article	IF	Citations
55	Drug development in advanced colorectal cancer: Challenges and opportunities. Current Oncology Reports, 2009, 11, 175-185.	4.0	4
56	Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. Oncologist, 2018, 23, 998-1003.	3.7	2